Piezowave

Myofascial Acoustic Compression Therapy (MyACT) harnesses the power of acoustic waves to target tissues at various depths, applying compression and manipulation to stimulate the body's innate healing mechanisms. Utilizing advanced PiezoWave2 technology, MyACT is employed to address both acute and chronic pain in muscles, tendons, and joints.

Developed by Richard Wolf, the PiezoWave2 seamlessly integrates the orthopedic applications of Extracorporeal Shock Wave Therapy (ESWT) with Trigger Point Shock Wave Therapy (TPST), two highly effective, non-surgical methods for managing chronic musculoskeletal pain.

The PiezoWave2 significantly broadens the scope of applications for treating myofascial pain syndrome. Its extracorporeal, targeted shock waves enable precise diagnosis and therapy of active and latent trigger points—those hypersensitive areas within tense muscles.

How It Operates:

The PiezoWave2 administers mechanical energy in the form of sound waves to specific tissues, including tenocytes in tendons, fibroblasts in ligaments and skin, osteocytes in bones, chondrocytes in articular cartilage, and endothelial cells in blood vessels—all highly responsive to mechanical stimulation. It then pinpoints trigger points, delivering meticulously focused acoustic pulses that reach the desired depth, ranging from 0.5mm to 3 cm depending on the therapy source. This promotes cellular repair by enhancing blood circulation and diminishing pain.

Extracorporeal shock waves have been effectively employed in managing chronic pain in Europe since the early 1990s. Moreover, MyACT/PiezoWave2 has been used for the past 23 years in Germany. Now, it has gained FDA registration as a Class 1 Modality in the United States.

What Can It Treat?

In all scenarios, the PiezoWave2 serves as a non-invasive alternative to surgery. Shockwave treatments have proven effective for various musculoskeletal conditions, including but not limited to: